Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for Cocaine Dependence
NCT01486810Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Dec 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lisdexamfetamine in cocaine dependence, sponsored by New York State Psychiatric Institute. Primary endpoints: Number of Participants Maintained on the Maximum Lisdexamfetamine Daily Dose at 1 week and Mean Maximum Maintained Dose of Lisdexamfetamine at 8 weeks. Started Dec 2011; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
cocaine dependence
Beyond the preview
Go deeper on NCT01486810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486810.